SOTIO is part of the PPF Group, one of the largest investment groups in Central and Eastern Europe. SOTIO is leading the efforts of PPF Group to build a diverse biotechnology portfolio through its own R&D, collaborations, in-licensing, minority investments and M&A. The most advanced program in its portfolio is a proprietary platform of active cellular immunotherapy on the basis of dendritic cells, currently in Phase III international clinical study.